What Sparked AbCellera Biologics To Soar Over 9% After Hours

Benzinga

02/25

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trending on Wednesday.

Earnings Beat Drives After-Hours Rally

Shares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.

AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.

Its revenue also increased by $39.80 million from a year earlier.

The fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.

Trading Metrics, Technical Analysis

AbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.

It has a Relative Strength Index (RSI) of 44.92.

The stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.

Price Action: ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.

The stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.

Benzinga's Edge Stock Rankings indicate that ABCL has a negative price trend across all time frames.

Photo courtesy: santima.studio / Shutterstock

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2614701768"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614701768\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614701768?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 16:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614701768","market":"hk","top_or_hot":-1,"title":"What Sparked AbCellera Biologics To Soar Over 9% After Hours","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. </strong>(NASDAQ:ABCL) shares are trending on Wednesday.</p>\n<h2><strong>Earnings Beat Drives After-Hours Rally</strong></h2>\n<p>Shares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.</p>\n<p>AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.</p>\n<p>Its revenue also increased by $39.80 million from a year earlier.</p>\n<p>The fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.</p>\n<h2>Trading Metrics, Technical Analysis</h2>\n<p>AbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.</p>\n<p>It has a Relative Strength Index (RSI) of 44.92.</p>\n<p>The stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.</p>\n<p><strong>Price Action: </strong>ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.</p>\n<p>The stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.</p>\n<p><strong>Benzinga's Edge Stock Rankings</strong> indicate that ABCL has a negative price trend across all time frames.</p>\n<figure><img decoding=\"async\" height=\"265\" loading=\"lazy\" sizes=\"(max-width: 432px) 100vw, 432px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587.png 432w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587-300x184.png 300w\" width=\"432\"/></figure>\n<p><em>Photo courtesy: santima.studio / Shutterstock</em></p>\n<p><strong>Disclaimer:</strong> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Sparked AbCellera Biologics To Soar Over 9% After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Sparked AbCellera Biologics To Soar Over 9% After Hours\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2026-02-25 16:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. </strong>(NASDAQ:ABCL) shares are trending on Wednesday.</p>\n<h2><strong>Earnings Beat Drives After-Hours Rally</strong></h2>\n<p>Shares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.</p>\n<p>AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.</p>\n<p>Its revenue also increased by $39.80 million from a year earlier.</p>\n<p>The fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.</p>\n<h2>Trading Metrics, Technical Analysis</h2>\n<p>AbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.</p>\n<p>It has a Relative Strength Index (RSI) of 44.92.</p>\n<p>The stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.</p>\n<p><strong>Price Action: </strong>ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.</p>\n<p>The stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.</p>\n<p><strong>Benzinga's Edge Stock Rankings</strong> indicate that ABCL has a negative price trend across all time frames.</p>\n<figure><img decoding=\"async\" height=\"265\" loading=\"lazy\" sizes=\"(max-width: 432px) 100vw, 432px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587.png 432w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/25024241/image-587-300x184.png 300w\" width=\"432\"/></figure>\n<p><em>Photo courtesy: santima.studio / Shutterstock</em></p>\n<p><strong>Disclaimer:</strong> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4150","symbol_name":"賭場與賭博","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/26/02/50841437/what-sparked-abcellera-biologics-to-soar-over-9-after-hours","article_id":"2614701768","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614701768","pubTimestamp":1772009491,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4150":"赌场与赌博","ABCL":"AbCellera Biologics","BK4535":"淡马锡持仓","BK4121":"生命科学工具和服务","RSI":"Rush Street Interactive, Inc."},"translate_title":"是什么引发AbCellera Biologics盘后飙升超过9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1.5,"RSI":1},"content_text":"AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trending on Wednesday.\nEarnings Beat Drives After-Hours Rally\nShares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.\nAbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.\nIts revenue also increased by $39.80 million from a year earlier.\nThe fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.\nTrading Metrics, Technical Analysis\nAbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.\nIt has a Relative Strength Index (RSI) of 44.92.\nThe stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.\nPrice Action: ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.\nThe stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.\nBenzinga's Edge Stock Rankings indicate that ABCL has a negative price trend across all time frames.\n\nPhoto courtesy: santima.studio / Shutterstock\nDisclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}